Related Experiment Video

Updated: Dec 13, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.2K

Short- and long-term outcomes following percutaneous coronary intervention in hepatitis C virus seropositive patients

Ahmed Hussein1, Mohamed Abdel Ghany2, Hossam Eldin M Mahmoud3

  • 1Department of Internal Medicine, Faculty of Medicine, Sohag University, Nasser city, Sohag, 82524, Egypt. forahmedaly@yahoo.com.

The Egyptian Heart Journal : (EHJ) : Official Bulletin of the Egyptian Society of Cardiology
|July 27, 2020
PubMed

Insights

Hepatitis C virus (HCV) infection did not significantly impact major adverse cardiovascular events or in-stent restenosis after percutaneous coronary intervention (PCI) in a 1-year follow-up study. This finding suggests HCV seropositivity is not a risk factor for PCI outcomes.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Vascular Medicine

Background:

  • Hepatitis C virus (HCV) infection is increasingly linked to atherosclerosis and coronary artery disease (CAD).
  • Cardiovascular risk factors like diabetes and dyslipidemia may influence outcomes after percutaneous coronary intervention (PCI).
  • The potential impact of HCV on PCI outcomes warrants investigation.

Purpose of the Study:

  • To investigate the impact of Hepatitis C virus (HCV) seropositivity on outcomes following percutaneous coronary intervention (PCI).

Main Methods:

  • A multi-center prospective cohort study involving 400 patients undergoing elective PCI with drug-eluting stents.
  • Patients were divided into two groups: 200 HCV seropositive (untreated) and 200 HCV seronegative.
  • One-year follow-up assessed major adverse cardiovascular events (MACEs) and clinical in-stent restenosis.

Main Results:

  • HCV seropositivity did not show a higher hazard for MACEs (adjusted HR 0.74; p=0.302) or clinical in-stent restenosis (adjusted HR 1.70; p=0.28) after 12 months.
  • Individual cardiovascular outcomes, including target lesion revascularization, myocardial infarction, stroke, stent thrombosis, bleeding, CABG, and cardiac/non-cardiac death, were not significantly different.
  • Multivariate Cox hazard regression analysis adjusted for confounding factors.

Conclusions:

  • HCV seropositivity was found to have no significant impact on MACEs, specific cardiovascular outcomes, or clinical in-stent restenosis within one year post-PCI.
  • The study suggests that HCV status does not adversely affect short-term outcomes after PCI.
Abstract

Keywords:
Clinical in-stent restenosisHCV seropositivityMACEsPCI

More Related Videos

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.5K
Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy14:52

Re-Arterialized Rat Partial Liver Transplantation with an in vivo Vessel-Oriented 70% Hepatectomy

Published on: April 8, 2018

12.1K

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
163
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
107
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
142
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
196